Skip to main content
SpringerLink
Log in

Individualizing Osteoporosis Therapy

  • Chapter
Osteoporosis: Genetics, Prevention and Treatment

Part of the book series: Endocrine Updates ((ENDO,volume 3))

  • 91 Accesses

Abstract

Every woman should consider prevention of postmenopausal osteoporosis at time of menopause with FDA approved antiresorptive therapies and adequate calcium and vitamin D. Every woman with established osteoporosis should consider treatment with antiresorptive therapies and adequate calcium and vitamin D.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC et al 1996 Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348: 1535–1541.

    Article  PubMed  CAS  Google Scholar 

  2. Brumsen C, Hamdy NA, Papapoulos SE 1997 Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine 76: 266–283.

    Article  PubMed  CAS  Google Scholar 

  3. Bryant HU, Dere WH 1998 Selective estrogen receptor modulators: an alternative to hormonal replacement therapy. Proc Soc Ex Biol Medicine. 217: 45–52.

    CAS  Google Scholar 

  4. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR 1995 For the study of osteoporotic fractures study group estrogen replacement therapy and fractures in older women. Ann Intern Med 122: 9–16.

    PubMed  CAS  Google Scholar 

  5. Chapuy MC, Arlot ME, Duboeuf F et al 1992 Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 328: 460–464.

    Google Scholar 

  6. Chesnut C, Baylink DJ, Doyle D, Genant H, Harris S, Kiel DP, LeBoff M, Stock JL, Gimona A, Andriano K, Richardson R for the PROOF study group 1998 Salmon calcitonin nasal spray prevents vertebral fractures in established osteoporosis. Further interim results of the PROOF study. In Program/Proceedings of the European Foundation for Osteoporosis, September 11-15; Berlin.

    Google Scholar 

  7. Christiansen C, Riis BJ 1990 17-beta estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women. J Clin Endocrinol Metab 71: 836–841.

    Article  PubMed  CAS  Google Scholar 

  8. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JF 1995 The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332: 1589–1593.

    Article  PubMed  CAS  Google Scholar 

  9. Cummings SR, Norton L, Eckert S, Grady D, Cauley J, Knickerbocker R, Black DM, Nickelsen T, Glusman J, Krueger K for the MORE investigators 1998 Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in postmenopausal women. Two year findings from the multiple outcomes of raloxifene evaluation (MORE) trial, (abstract). In Program/Proceedings of the American Society of Clinical Oncology, Thirty-Fourth Annual Meeting, May 16–19; Philadelphia(PA): WB Saunders Company/Mack Printing Group, p 2a. Abstract 3

    Google Scholar 

  10. Dawson-Hughes B, Harris SS, Krall EA, Dallai GE 1997 Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 337: 670–676.

    Article  PubMed  CAS  Google Scholar 

  11. De Groen PC, Lubbe CF, Hirsch LF, Daifotis A, Stephenson W, Freedholm D, Pryor-Tilootson S, Seleznick MJ, Pinkas H, Wang KH 1996 Esophagitis associated with the use of alendronate. N Engl J Med 335: 1016–1021.

    Article  Google Scholar 

  12. Delmas PD, Bjarnason NH, Mitlak BH et al 1997 Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337: 1641–1647.

    Article  PubMed  CAS  Google Scholar 

  13. Draper MW, Flowers DE, Huster WJ et al 1996 A controlled trial of raloxifene (LY139481): impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 11: 835–842.

    Article  PubMed  CAS  Google Scholar 

  14. Ettinger B, Black D, Cummings S, Genant H, Gluer C, Lips P, Knickerbocker R, Eckert S, Nickelsen T, Mitlak B, for the MORE Study Group 1998. Raloxifene reduces the risk of incident vertebral fractures: 24-month interim analyses. In: Program/Proceedings of the European Foundation for Osteoporosis September 11-15; Berlin.

    Google Scholar 

  15. Felsen DT, Zhang Y, Hannan MT et al 1993 The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 329: 1141–1146.

    Article  Google Scholar 

  16. Fleisch HA 1997 Bisphosphonates: preclinical aspects and use in osteoporosis. Ann Int Medi 29: 55–62.

    Article  CAS  Google Scholar 

  17. Genant HK, Lucas J, Weiss S, Akin M, Emkey R, et al 1997 Low dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium and lipid levels: estratab osteoporosis study group. Arch Int Med 155: 2609–2615.

    Article  Google Scholar 

  18. Heaney RP, Draper MW 1997 Raloxifene and estrogen: comparative bone remodeling kinetics. J Clin Endocrinol Metab 82: 3425–3429.

    Article  PubMed  CAS  Google Scholar 

  19. Heaney RP, Yates AJ, Santora AC II 1997 Bisphosphonate effects and the bone remodeling transient. J Bone Miner Res 12: 1143–1151.

    Article  PubMed  CAS  Google Scholar 

  20. Heaney RP 1998 Nonpharmacologic prevention: nutrition and exercise in Osteoporosis: Diagnosis and Management. Martin Dunitz, Ltd., London.

    Google Scholar 

  21. Heikinheimo RJ, Inkovaara JA, Harju EJ et al 1992 Annual injection of vitamin D and fractures of aged bones. Calcif Tissue Int 51: 105–110.

    Article  PubMed  CAS  Google Scholar 

  22. Holick MF 1994 Vitamin D — new horizons for the 21st century. Am J Clin Nutr 60: 619–630.

    PubMed  CAS  Google Scholar 

  23. Hosking D, Chilvers CE, Christiansen C, Ravn P, Wasnich R, Ross P, Mc Clung M, Balske A, Thompson D, Daley M, Yates AJ 1998 Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early postmenopausal intervention cohort study group. N Engl J Med 338: 485–492.

    Article  PubMed  CAS  Google Scholar 

  24. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF 1995 Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Mineral Res 10: 1478–1487.

    Article  CAS  Google Scholar 

  25. Hughes DE, Dai A, Tiffee JC, Li HH, Mundy GR, Boyce BF 1996 Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nature Med 2: 1132–1136.

    Article  PubMed  CAS  Google Scholar 

  26. Jordan VC, Glusman JE, Eckert S, Lippman M, Powles T, Costa A, Morrow M, Norton L 1998 Incident primary breast cancers are reduced by raloxifene: integrated data from multicenter, double blind, randomized trials in 12,000 postmenopausal women (abstract). In Program/Proceedings of the American Society of Clinical Oncology, Thirty-Fourth Annual Meeting, May 16–19; Philadelphia(PA): WB Saunders Company/Mack Printing Group, p 122a. Abstract 466.

    Google Scholar 

  27. Koster JC, Hacking WH, Mulder H 1996 Diminished effect of etidronate in vitamin D deficient osteopenic postmenopausal women. Eur J Clin Pharm 52: 145–147

    Article  Google Scholar 

  28. Liberman UA, Weiss SR, Broil J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Eng J Med 333: 1437–1443.

    Article  CAS  Google Scholar 

  29. Lindsay R, Thome JF 1990 Estrogen treatment of patients with established osteoporosis. Obstet Gynecol 76: 290–295.

    PubMed  CAS  Google Scholar 

  30. Luengo M, Pons F, Martinez de Osaba MJ, Picado C 1994 Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: a two year follow up study. Thorax 49: 1099–1102.

    Article  PubMed  CAS  Google Scholar 

  31. Lufkin EG, Wanner HW, O’Fallon WM et al 1992 Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Int Med 117: 1–9.

    PubMed  CAS  Google Scholar 

  32. Manolagas SC, Bellido T, Jilka RL 1995 New insights into the cellular, biochemical, and molecular basis of postmenopausal and senile osteoporosis: roles of IL-6 and gpl30. Int J Immunopharm 17: 109–116.

    Article  CAS  Google Scholar 

  33. Martin TJ, Moseley JM 1990 Calcitonin In Metabolic Bone Disease (L. Avioli and S. Krane, Eds.), Saunders, Philadelphia 131–154.

    Google Scholar 

  34. NIH Consensus Conference 1994 Optimal calcium intake. JAMA 272: 1942–1948.

    Article  Google Scholar 

  35. Overgaard K, Hansen MA, Jensen SB, Christiansen C 1992 Effect of salcatonin given intranasally on bone mass and fracture rate in established osteoporosis: a dose response study. BMJ 305: 556–561.

    Article  PubMed  CAS  Google Scholar 

  36. Pun KK, Chan LW 1989 Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures. Clin Therap 11: 205–209.

    CAS  Google Scholar 

  37. Rebar RW, Thomas MW, Gass MLS, Liu JH 1990 Problems of hormone therapy: evaluations, follow-up, complications. In the menopause. Serrano Symposium Norwell Massachusetts. 145–156.

    Google Scholar 

  38. Reginster JY, Meurmans L, Zegels B, Rovati LC, Minne HW, Giacovelli C, Taquet AN, Setnikar I, Collette J, Gosset C 1998 The effect of sodium fluoromonophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. Ann Int Med 129: 1–8.

    PubMed  CAS  Google Scholar 

  39. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG 1998 Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis: Glucocorticoid-induced osteoporosis intervention study group. N Engl J Med 339: 292–299.

    Article  PubMed  CAS  Google Scholar 

  40. Sass DA, Bowman AR, Yuan Z, Ma Y, Jee WS, Epstein S 1997 Alendronate prevents cyclosporin A induced osteopenia in the rat. Bone 21: 65–70.

    Article  PubMed  CAS  Google Scholar 

  41. Silverman SL, Greenwald M, Klein RA, Drinkwater B 1998 Effect of bone density information on decisions about hormonal replacement therapy: a randomized trial. Obstet Gynecol 89: 321–325.

    Article  Google Scholar 

  42. Shen V, Dempster DW, Birchman R, Xu R, Lindsay R 1993 Loss of cancellous bone mass and connectivity in ovariectomized rats can be restored by combined treatment with parathyroid hormone and estradiol. J Clin Invest 91: 2479–2487.

    Article  PubMed  CAS  Google Scholar 

  43. Sherwin B 1997 Estrogenic effects on the central nervous system: clinical aspects, in: estrogens and antiestrogens: basic and clinical aspects. Lindsay R, Dempster D, Jordan V Eds. Lippincott Raven, Philadelphia.

    Google Scholar 

  44. Vitte C, Fleisch H, Guenther HL 1996 Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast mediated resorption. Endocrinology 137: 2324–2333.

    Article  PubMed  CAS  Google Scholar 

  45. The Writing Group for the PEPI trial 1996 Effects of hormonal treatment on bone mineral density: results from the postmenopausal estrogen/progestin intervention trial. JAMA 276: 1389–1396.

    Article  Google Scholar 

Download references

Authors
  1. Stuart L. Silverman M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Cedars-Sinai Medical Center, Los Angeles, California, USA

    John S. Adams M.D.

  2. University of Kansas Medical School, Kansas City, Missouri, USA

    Barbara P. Lukert M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Science+Business Media New York

About this chapter

Cite this chapter

Silverman, S.L. (1999). Individualizing Osteoporosis Therapy. In: Adams, J.S., Lukert, B.P. (eds) Osteoporosis: Genetics, Prevention and Treatment. Endocrine Updates, vol 3. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5115-7_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-5115-7_10

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7327-8

  • Online ISBN: 978-1-4615-5115-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation